Junshi grants license to Hikma for toripalimab in Middle East and North Africa

Client(s) Shanghai Junshi Biosciences Co., Ltd.

Jones Day represented Shanghai Junshi Biosciences Co., Ltd. in its license agreement with Hikma Pharmaceuticals PLC for the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, in the Middle East and North Africa. Toripalimab is an anti-PD-1 monoclonal antibody approved for marketing in China for six indications to date. Over thirty toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical studies evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney, and skin, among others.